CN111518075B - Naphthalimide piperazine triazole compound and preparation method and application thereof - Google Patents
Naphthalimide piperazine triazole compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN111518075B CN111518075B CN202010305821.1A CN202010305821A CN111518075B CN 111518075 B CN111518075 B CN 111518075B CN 202010305821 A CN202010305821 A CN 202010305821A CN 111518075 B CN111518075 B CN 111518075B
- Authority
- CN
- China
- Prior art keywords
- naphthalimide
- compound
- piperazine
- preparation
- triazole compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 66
- -1 Naphthalimide piperazine triazole compound Chemical class 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 17
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 11
- 230000000843 anti-fungal effect Effects 0.000 claims abstract description 11
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 7
- 241000233866 Fungi Species 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 87
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 66
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 48
- 238000006243 chemical reaction Methods 0.000 claims description 47
- 239000002904 solvent Substances 0.000 claims description 25
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 241000191967 Staphylococcus aureus Species 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 241000222122 Candida albicans Species 0.000 claims description 8
- 229940095731 candida albicans Drugs 0.000 claims description 8
- 241001225321 Aspergillus fumigatus Species 0.000 claims description 7
- 229940091771 aspergillus fumigatus Drugs 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- FMCUPJKTGNBGEC-UHFFFAOYSA-N 1,2,4-triazol-4-amine Chemical compound NN1C=NN=C1 FMCUPJKTGNBGEC-UHFFFAOYSA-N 0.000 claims description 5
- DTUOTSLAFJCQHN-UHFFFAOYSA-N 4-bromo-1,8-naphthalic anhydride Chemical compound O=C1OC(=O)C2=CC=CC3=C2C1=CC=C3Br DTUOTSLAFJCQHN-UHFFFAOYSA-N 0.000 claims description 5
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 5
- 241000222173 Candida parapsilosis Species 0.000 claims description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 5
- 229940055022 candida parapsilosis Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 239000004246 zinc acetate Substances 0.000 claims description 5
- 241000222178 Candida tropicalis Species 0.000 claims description 4
- 241000194032 Enterococcus faecalis Species 0.000 claims description 4
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- 229960003085 meticillin Drugs 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 3
- 239000003889 eye drop Substances 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 3
- 159000000021 acetate salts Chemical class 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 20
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 241000192125 Firmicutes Species 0.000 abstract description 4
- 230000000845 anti-microbial effect Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 230000002924 anti-infective effect Effects 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 244000000010 microbial pathogen Species 0.000 abstract 1
- 239000005457 ice water Substances 0.000 description 40
- 239000000243 solution Substances 0.000 description 30
- 238000001035 drying Methods 0.000 description 25
- 238000001914 filtration Methods 0.000 description 24
- 239000007787 solid Substances 0.000 description 22
- 238000004809 thin layer chromatography Methods 0.000 description 21
- 238000004440 column chromatography Methods 0.000 description 20
- 238000002844 melting Methods 0.000 description 20
- 230000008018 melting Effects 0.000 description 20
- 238000000926 separation method Methods 0.000 description 20
- 238000005406 washing Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 10
- 229960004884 fluconazole Drugs 0.000 description 10
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- XBNNCHAVLVEGSF-UHFFFAOYSA-N piperazine;2h-triazole Chemical class C=1C=NNN=1.C1CNCCN1 XBNNCHAVLVEGSF-UHFFFAOYSA-N 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 3
- 229940029284 trichlorofluoromethane Drugs 0.000 description 3
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Chemical group CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000011185 polyoxyethylene (40) stearate Nutrition 0.000 description 2
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- IBLMYGXJKQIGSN-UHFFFAOYSA-N 1-(bromomethyl)-2,4-difluorobenzene Chemical compound FC1=CC=C(CBr)C(F)=C1 IBLMYGXJKQIGSN-UHFFFAOYSA-N 0.000 description 1
- SCBZBMXPJYMXRC-UHFFFAOYSA-N 1-(bromomethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(CBr)=C1 SCBZBMXPJYMXRC-UHFFFAOYSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- MYMSJFSOOQERIO-UHFFFAOYSA-N 1-bromodecane Chemical compound CCCCCCCCCCBr MYMSJFSOOQERIO-UHFFFAOYSA-N 0.000 description 1
- PBLNBZIONSLZBU-UHFFFAOYSA-N 1-bromododecane Chemical compound CCCCCCCCCCCCBr PBLNBZIONSLZBU-UHFFFAOYSA-N 0.000 description 1
- HNTGIJLWHDPAFN-UHFFFAOYSA-N 1-bromohexadecane Chemical compound CCCCCCCCCCCCCCCCBr HNTGIJLWHDPAFN-UHFFFAOYSA-N 0.000 description 1
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 1
- WSULSMOGMLRGKU-UHFFFAOYSA-N 1-bromooctadecane Chemical compound CCCCCCCCCCCCCCCCCCBr WSULSMOGMLRGKU-UHFFFAOYSA-N 0.000 description 1
- VMKOFRJSULQZRM-UHFFFAOYSA-N 1-bromooctane Chemical compound CCCCCCCCBr VMKOFRJSULQZRM-UHFFFAOYSA-N 0.000 description 1
- NNQDMQVWOWCVEM-UHFFFAOYSA-N 1-bromoprop-1-ene Chemical compound CC=CBr NNQDMQVWOWCVEM-UHFFFAOYSA-N 0.000 description 1
- XXFUZSHTIOFGNV-UHFFFAOYSA-N 1-bromoprop-1-yne Chemical compound CC#CBr XXFUZSHTIOFGNV-UHFFFAOYSA-N 0.000 description 1
- KOFZTCSTGIWCQG-UHFFFAOYSA-N 1-bromotetradecane Chemical compound CCCCCCCCCCCCCCBr KOFZTCSTGIWCQG-UHFFFAOYSA-N 0.000 description 1
- DDGRAFHHXYIQQR-UHFFFAOYSA-N 1-chloro-3-(chloromethyl)benzene Chemical compound ClCC1=CC=CC(Cl)=C1 DDGRAFHHXYIQQR-UHFFFAOYSA-N 0.000 description 1
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 1
- IRSVDHPYXFLLDS-UHFFFAOYSA-N 2,4-dichloro-1-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1Cl IRSVDHPYXFLLDS-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- LWZFANDGMFTDAV-WYDSMHRWSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-WYDSMHRWSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000005262 decarbonization Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000008149 soap solution Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a naphthalimide piperazine triazole compound, and a preparation method and application thereof, and belongs to the technical field of chemical synthesis. The naphthalimide piperazine triazole compound has certain inhibitory activity on one or more of gram-positive bacteria, gram-negative bacteria and fungi, can be used for preparing antibacterial and/or antifungal medicaments, has an opportunity to provide more safe and efficient diversified candidate medicaments for clinical antimicrobial treatment, and is beneficial to solving clinical treatment problems such as increasingly severe drug resistance, stubborn pathogenic microorganisms, newly-appeared harmful microorganisms and the like. The preparation raw materials are simple, cheap and easily available, the synthetic route is short, and the application in the anti-infection aspect has important significance.
Description
Technical Field
The invention belongs to the technical field of chemical synthesis, and particularly relates to a naphthalimide piperazine triazole compound, and a preparation method and application thereof.
Background
The naphthalimide is an aromatic nitrogen-oxygen heterocyclic compound containing six-membered cyclic imide and naphthalene rings, has a larger electron-pushing conjugated system, and has a special structure favorable for intramolecular/intermolecular electron transfer, so that the special rigid fused ring structure is easy to interact with biological active sites such as enzymes, receptors, DNA and the like through various non-covalent bond interactions such as hydrogen bonds, hydrophobic interaction, pi-pi accumulation, electrostatic interaction and the like, thereby showing wide application potential. In recent years, especially in the field of pharmaceutical chemistry, the compounds show great development value and broad application prospects, and more research works are devoted to the research and development of drugs with naphthalimide as a basic skeleton, such as in the aspects of anti-tumor, anti-bacterial, anti-fungal, anti-viral, anti-inflammatory, anti-depression, medical diagnosis and the like. But the naphthalimide ring cannot be widely applied clinically due to the solubility, hepatotoxicity and other toxic and side effects, but the naphthalimide ring is easy to modify the structure and can conveniently introduce various functional groups, thereby playing an increasingly important role in the pharmaceutical field.
Disclosure of Invention
In view of the above, an object of the present invention is to provide naphthoylimine piperazine triazole compounds and pharmaceutically acceptable salts thereof; the invention also aims to provide a preparation method of the naphthalimide piperazine triazole compound and the pharmaceutically acceptable salt thereof; the third purpose of the invention is to provide the application of the naphthalimide piperazine triazole compound and the pharmaceutically acceptable salt thereof in preparing antibacterial and/or antifungal medicaments; the invention also aims to provide a preparation containing the naphthalimide piperazine triazole compound and a pharmaceutically acceptable salt thereof.
In order to achieve the purpose, the invention provides the following technical scheme:
1. the structure of the naphthalimide piperazine triazole compound and the pharmaceutically acceptable salt thereof is shown as the general formula I:
in the formula:
r is hydrogen, alkyl, aryl, halomethylene, alcoholic methylene, aldehyde group, sulfhydryl, alkynyl, alkenyl, cyano or ester group.
Preferably, R is hydrogen, ethyl, hexyl, octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, alkenyl, alkynyl, p-chlorophenyl, m-chlorophenyl, 2, 4-dichlorophenyl, p-fluorophenyl, m-fluorophenyl, 2, 4-difluorophenyl, cyano, hydroxyethyl, methoxyacyl or ethoxyacyl.
Preferably, it is any one of the following compounds:
preferably, the pharmaceutically acceptable salt is hydrochloride, nitrate or acetate.
2. The preparation method of the naphthalimide piperazine triazole compound and the pharmaceutically acceptable salt thereof comprises the following steps:
a. preparation of intermediate II: 4-bromo-1, 8-naphthalic anhydride is used as an initial raw material, ethanol is used as a solvent, zinc acetate is used as a catalyst, and the mixture reacts with 4-amino-1, 2, 4-triazole to obtain an intermediate II;
b. preparation of intermediate III: taking the intermediate II as a starting material, taking ethylene glycol monomethyl ether as a solvent, and reacting with anhydrous piperazine to obtain an intermediate III;
c. the preparation method of the naphthalimide piperazine triazole compound shown in the general formula I comprises the step of reacting different halides with the intermediate III serving as a starting material, acetonitrile serving as a solvent and potassium carbonate serving as a catalyst to obtain the naphthalimide piperazine triazole compound shown in the general formula I.
In a preferred embodiment of the method of the invention,
in the step a, the reaction temperature is 80 ℃; the molar ratio of the 4-bromo-1, 8-naphthalic anhydride, 4-amino-1, 2, 4-triazole and zinc acetate is 1;
in the step b, the reaction temperature is 90 ℃; the molar ratio of the intermediate II to the anhydrous piperazine is 1;
in the step c, the reaction temperature is 80 ℃; the molar ratio of intermediate III, different halides and potassium carbonate is 1.07.
3. The naphthalimide piperazine triazole compound and the application of the medicinal salt thereof in preparing antibacterial and/or antifungal medicaments.
Preferably, the bacteria are one or more of methicillin-resistant staphylococcus aureus, enterococcus faecalis, staphylococcus aureus ATCC25923, staphylococcus aureus ATCC29213, klebsiella pneumoniae, escherichia coli ATCC25922, pseudomonas aeruginosa ATCC27853, or acinetobacter baumannii; the fungi is one or more of Candida albicans, candida tropicalis, aspergillus fumigatus, candida albicans ATCC90023 or Candida parapsilosis ATCC 20019.
4. The preparation of the naphthalimide piperazine triazole compound and the pharmaceutically acceptable salt thereof.
Preferably, the preparation is one of tablets, capsules, granules, injections, powder injections, eye drops, liniments, suppositories, ointments or aerosols.
The invention has the beneficial effects that: the invention provides a naphthalimide piperazine triazole compound and a preparation method and application thereof, the invention utilizes a drug combination principle to introduce important antibacterial fragment 1,2, 4-triazole at N position of naphthalimide, and then introduces different substituents by piperazine bridging, a series of naphthalimide piperazine triazole compounds with novel structures are designed and synthesized, and the compounds are detected by in vitro antimicrobial activity to find that the compounds have certain inhibitory activity on one or more of gram-positive bacteria (methicillin-resistant staphylococcus aureus, enterococcus faecalis, staphylococcus aureus ATCC25923, staphylococcus aureus ATCC 29213), gram-negative bacteria (Klebsiella pneumoniae, escherichia coli ATCC25922, pseudomonas aeruginosa ATCC27853, acinetobacter baumannii) and fungi (candida albicans, candida tropicalis, aspergillus fumigatus, candida albicans ATCC90023, candida parapsilosis ATCC 20019), and can be used for preparing antibacterial and/or antifungal drugs, thereby providing more safe and efficient clinical antimicrobial therapy for more drugs, and being beneficial to solving the serious drug resistance of clinical and serious biological resistance of stubborn microorganisms. The preparation raw materials are simple, cheap and easy to obtain, the synthetic route is short, and the application in the anti-infection aspect has important significance.
Additional advantages, objects, and features of the invention will be set forth in part in the description which follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from practice of the invention. The objectives and other advantages of the invention may be realized and attained by the means of the instrumentalities and combinations particularly pointed out hereinafter.
Detailed Description
The following embodiments of the present invention are provided by way of specific examples, and other advantages and effects of the present invention will be readily apparent to those skilled in the art from the disclosure herein. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Experimental example 1
Preparation of intermediate II
A50 mL round-bottomed flask was charged with 4-bromo-1, 8-naphthalic anhydride (192.4 mg, 0.72mmol), 4-amino-1, 2, 4-triazole (90.8 mg, 1.08mmol), zinc acetate (12.8 mg, 0.07mmol) as a catalyst, ethanol (5 mL) as a solvent, and refluxed at 80 ℃ overnight. Pouring the reaction mixture into hydrochloric acid solution (10mL, 0.05mol/L), filtering to obtain a filter cake, and separatingThe filter cake was washed with water, ethanol and acetone, respectively. After drying, the mixture was subjected to column chromatography (developer: dichloromethane) to give intermediate II (222 mg) as a yellow solid in 90.0% yield. 1 H NMR(600MHz,DMSO-d6)δ8.89(s,3H,naphthalimide-H,triazole-H),8.53(d,J=3.1Hz,1H,naphthalimide-H),8.32(d,J=4.4Hz,1H,naphthalimide-H),7.70(d,J=8.2Hz,1H,naphthalimide-H),6.97(s,1H,naphthalimide-H)ppm。
Experimental example 2
Preparation of intermediate III
A250 mL round bottom flask was charged with intermediate II (5.0 g,14.6 mmol) and anhydrous piperazine (3.8 g,43.8 mmol) in ethylene glycol monomethyl ether (100 mL) as a solvent, reacted at 90 deg.C, followed by thin layer chromatography until the reaction was complete, cooled to room temperature, and the solvent was removed to give intermediate III (4.2 g) as a golden yellow solid in 82.3% yield. 1 H NMR(600MHz,DMSO-d6)δ8.79(s,2H,triazole-H),8.59(d,J=3.6Hz,1H,naphthalimide-H),8.56(d,J=4.1Hz,1H,naphthalimide-H),8.49(d,J=8.3Hz,1H,naphthalimide-H),7.90(d,J=7.9Hz,1H,naphthalimide-H),7.44(d,J=8.2Hz,1H,naphthalimide-H),4.23(s,1H,NH),3.37(s,4H,piperidine-H),2.97(s,4H,piperidine-H)ppm。
Experimental example 3
Preparation of Compound I-1
A50 mL round bottom flask was charged with intermediate III (466 mg,1.4 mmol), bromoethane (160mg, 1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and carrying out post-treatment such as column chromatography separation and drying to obtain the compound I-1 (353 mg), wherein the yield is as follows: 65.4 percent; a yellow solid; melting point: 155-156 ℃. 1 H NMR(600MHz,DMSO-d6)δ8.80(s,2H,triazole-H),8.58(d,J=3.1Hz,1H,naphthalimide-H),8.57(d,J=4.4Hz,1H,naphthalimide-H),8.49(d,J=8.2Hz,1H,naphthalimide-H),7.89(s,1H,naphthalimide-H),7.41(d,J=8.2Hz,1H,naphthalimide-H),2.71(t,4H,piperidine-H),2.50(t,4H,piperidine-H),2.48(s,2H,CH 2 CH 3 ),1.08(s,3H,CH 3 ).
Experimental example 4
Preparation of Compound I-2
A50 mL round bottom flask was charged with intermediate III (466 mg,1.4 mmol), bromohexane (230mg, 1.5 mmol), and potassium carbonate (0.82g, 5.6 mmol) in acetonitrile (15 mL), refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-2 (350 mg) with a yield: 57.9 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.65(d,J=6.9Hz,1H,naphthalimide-H),8.58(d,J=7.9Hz,1H,naphthalimide-H),8.54(d,J=8.3Hz,1H,naphthalimide-H),8.31(s,2H,triazole-H),7.77(t,J=7.6Hz,1H,naphthalimide-H),7.28(s,1H,naphthalimide-H),3.40(s,4H,piperidine-H),2.81(s,4H,piperidine-H),2.53–2.49(m,2H,CH 2 (CH 2 ) 4 CH 3 ),1.58(s,2H,CH 2 (CH 2 ) 3 CH 3 ),1.34(s,6H,(CH 2 ) 3 CH 3 ),0.91(s,3H,CH 3 )ppm。
experimental example 5
Preparation of Compound I-3
A50 mL round-bottom flask was charged with intermediate III (466 mg,1.4 mmol), octylbromide (290mg, 1.5 mmol), and potassium carbonate (0.82g, 5.6 mmol) in acetonitrile (15 mL), refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water,after column chromatography separation, drying and the like, compound I-3 (420 mg) was obtained, yield: 61.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.66(d,J=6.9Hz,1H,naphthalimide-H),8.58(d,J=7.9Hz,1H,naphthalimide-H),8.53(d,J=8.3Hz,1H,naphthalimide-H),8.32(s,2H,triazole-H),7.77(t,J=7.6Hz,1H,naphthalimide-H),7.28(s,1H,naphthalimide-H),3.41(s,4H,piperidine-H),2.80(s,4H,piperidine-H),2.53(m,2H,CH 2 (CH 2 ) 6 CH 3 ),1.58(m,2H,CH 2 (CH 2 ) 5 CH 3 ),1.34(m,10H,(CH 2 ) 5 CH 3 ),0.91(s,3H,CH 3 )ppm。
experimental example 6
Preparation of Compound I-4
A50 mL round bottom flask was charged with intermediate III (466 mg,1.4 mmol), bromodecane (332mg, 1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-4 (475 mg) with a yield: 65.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(400MHz,DMSO-d 6 )δ11.16(bs,1H,NNH),8.55(d,J=8.3Hz,1H,naphthalimide-7-H),8.44(d,J=8.2Hz,1H,naphthalimide-5-H),8.34(d,J=7.7Hz,1H,naphthalimide-2-H),8.29(s,1H,CHN),7.65(t,J=7.7Hz,1H,naphthalimide-6-H),7.19(d,J=8.4Hz,1H,naphthalimide-3-H),4.81(bs,1H,OH),4.15(t,J=12.4Hz,2H,NCH 2 CH 2 ),4.09(t,J=12.4Hz,2H,CH 2 CH 2 OH),3.60(t,J=11.5Hz,2H,CH 2 OH),2.65(t,J=7.4Hz,2H,CH 2 CH 2 CH 2 CH 3 ),1.67(t,J=11.0Hz,4H,NCH 2 CH 2 ,CH 2 CH 2 CH 2 CH 3 ),1.39(m,6H,NCH 2 CH 2 CH 2 CH 2 CH 3 ,CH 2 CH 2 CH 2 CH 3 ),0.93(m,6H,CH 3 )ppm。
experimental example 7
Preparation of Compound I-5
A50 mL round bottom flask was charged with intermediate III (466 mg,1.4 mmol), bromododecane (332mg, 1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-5 (475 mg) with a yield: 65.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.66(d,J=7.2Hz,1H,naphthalimide-H),8.58(d,J=8.2Hz,1H,naphthalimide-H),8.54(d,J=8.4Hz,1H,naphthalimide-H),8.31(s,2H,triazole-H),7.77(d,J=8.3Hz,1H,naphthalimide-H),7.28(s,1H,naphthalimide-H),3.41(s,4H,piperidine-H),2.81(s,4H,piperidine-H),2.52(d,J=7.6Hz,2H,CH 2 (CH 2 ) 12 CH 3 ),1.59–1.56(m,2H,CH 2 (CH 2 ) 11 CH 3 ),1.29(d,J=18.5Hz,22H,(CH 2 ) 11 CH 3 ),0.89(s,3H,CH 3 )ppm。
experimental example 8
Preparation of Compound I-6
A50 mL round-bottom flask was charged with intermediate III (466 mg,1.4 mmol), bromotetradecane (415mg, 1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-6 (475 mg) with a yield: 65.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.66(d,J=7.2Hz,1H,naphthalimide-H),8.59(d,J=8.2Hz,1H,naphthalimide-H),8.54(d,J=8.4Hz,1H,naphthalimide-H),8.31(s,2H,triazole-H),7.77(d,J=8.3Hz,1H,naphthalimide-H)),7.28(s,1H,naphthalimide-H),3.41(s,4H,piperidine-H),2.81(s,4H,piperidine-H),2.53(d,J=7.6Hz,2H,CH 2 (CH 2 ) 12 CH 3 ),1.59(m,2H,CH 2 (CH 2 ) 11 CH 3 ),1.29(d,J=18.5Hz,18H,(CH 2 ) 9 CH 3 ),0.89(s,3H,CH 3 )ppm。
experimental example 9
Preparation of Compound I-7
A50 mL round bottom flask was charged with intermediate III (466 mg,1.4 mmol), bromohexadecane (457 mg,1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and carrying out post-treatment such as column chromatography separation and drying to obtain compound I-7 (461 mg), wherein the yield is as follows: 66.9 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.67–8.65(m,1H,naphthalimide-H),8.58(d,J=8.2Hz,1H,naphthalimide-H),8.54(d,J=8.4Hz,1H,naphthalimide-H),8.31(s,2H,triazole-H),7.79–7.76(m,1H,naphthalimide-H),7.28(s,1H,naphthalimide-H),3.40(s,4H,piperidine-H),2.81(s,4H,piperidine-H),2.53–2.48(m,2H,CH 2 (CH 2 ) 14 CH 3 ),1.58(s,2H,CH 2 (CH 2 ) 13 CH 3 ),1.34(s,4H,CH 2 (CH 2 ) 11 CH 3 ),1.28(d,J=20.2Hz,22H,(CH 2 ) 11 CH 3 ),0.88(t,J=7.0Hz,3H,CH 3 )ppm。
experimental example 10
Preparation of Compound I-8
A50 mL round bottom flask was charged with intermediate III (466 mg,1.4 mmol), bromooctadecane (500mg, 1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-8 (390 mg) with a yield: 64.9 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.65(d,J=7.1Hz,1H,naphthalimide-H),8.57(d,J=8.2Hz,1H,naphthalimide-H),8.54(d,J=8.4Hz,1H,naphthalimide-H),8.31(s,2H,triazole-H),7.77(s,1H,naphthalimide-H),7.26(s,1H,naphthalimide-H),3.41(s,4H,piperidine-H),2.81(s,4H,piperidine-H),2.52(d,J=7.6Hz,2H,CH 2 (CH 2 ) 16 CH 3 ),1.59–1.57(m,2H,CH 2 (CH 2 ) 15 CH 3 ),1.26(m,30H,(CH 2 ) 15 CH 3 ),0.88(s,3H,CH 3 )ppm。
experimental example 11
Preparation of Compound I-9
A50 mL round bottom flask was charged with intermediate III (466 mg,1.4 mmol), bromoethanol (186mg, 1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-9 (323 mg) with a yield: 66.9 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.66(d,J=6.9Hz,1H,naphthalimide-H),8.60(d,J=8.1Hz,1H,naphthalimide-H),8.53(d,J=8.3Hz,1H,naphthalimide-H),8.32(s,2H,triazole-H),7.78(t,J=7.6Hz,1H,naphthalimide-H),7.29(d,J=8.2Hz),3.78(s,4H,piperidine-H),3.43(s,6H,piperidine-H,CH 2 CH 2 OH),2.99–2.97(t,2H,CH 2 CH 2 OH)ppm。
experimental example 12
Preparation of Compound I-10
A50 mL round bottom flask was charged with intermediate III (466 mg,1.4 mmol), methyl bromoacetate (230mg, 1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-10 (473 mg) with a yield: 75.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.67(d,J=7.3Hz,1H,naphthalimide-H),8.60(d,J=8.1Hz,1H,naphthalimide-H),8.54(d,J=8.4Hz,1H,naphthalimide-H),8.32(s,2H,triazole-H),7.78(t,J=7.9Hz,1H,naphthalimide-H),7.29(d,J=8.2Hz,1H,naphthalimide-H),3.78(s,3H,CH 3 ),3.43(s,6H,NCH 2 CO,piperidine-H),2.99–2.97(m,4H,piperidine-H)ppm。
experimental example 13
Preparation of Compound I-11
A50 mL round-bottomed flask was charged with intermediate III (466 mg,1.4 mmol), ethyl bromoacetate (249mg, 1.5 mmol), and potassium carbonate (0.82g, 5.6 mmol) in acetonitrile (15 mL) at 80 ℃ under reflux for about 10h, followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and carrying out post-treatment such as column chromatography separation and drying to obtain the compound I-11 (315 mg) with yield: 75.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,DMSO)δ8.79(s,2H,triazole-H),8.57(t,J=8.2Hz,2H,naphthalimide-H),8.49(d,J=8.2Hz,1H,naphthalimide-H),7.90(t,J=7.9Hz,1H,naphthalimide-H),7.43(d,J=8.2Hz,1H,naphthalimide-H),4.13(d,J=7.1Hz,2H,NCH 2 CO),3.40(s,2H,OCH 2 CH 3 ),3.33(s,4H,piperidine-H),2.90–2.87(m,4H,piperidine-H),1.23(t,J=7.1Hz,3H,CH 3 )ppm。
experimental example 14
Preparation of Compound I-12
A50 mL round bottom flask was charged with intermediate III (466 mg,1.4 mmol), bromopropene (182mg, 1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and carrying out post-treatment such as column chromatography separation and drying to obtain the compound I-12 (315 mg) with yield: 75.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.66(d,J=7.2Hz,1H,naphthalimide-H),8.58(d,J=8.2Hz,1H,naphthalimide-H),8.54(d,J=8.4Hz,1H,naphthalimide-H),8.30(s,2H,triazole-H),7.79–7.75(m,1H,naphthalimide-H),7.29–7.27(m,1H,naphthalimide-H),5.94(ddt,J=13.2,10.1,6.6Hz,1H,CH=CH 2 ),5.31–5.23(m,2H,CH=CH 2 ),3.41(s,4H,piperidine-H),3.19(d,J=6.2Hz,2H),2.83(s,4H,piperidine-H)ppm。
experimental example 15
Preparation of Compound I-13
A50 mL round bottom flask was charged with intermediate III (466 mg, 1.4mmol), bromopropyne (179mg, 1.5mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-13 (315 mg) with a yield: 75.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.67(d,J=7.3Hz,1H,naphthalimide-H),8.59(d,J=8.2Hz,1H,naphthalimide-H),8.56(d,J=8.4Hz,1H,naphthalimide-H),8.31(s,2H,triazole-H),7.79(s,1H,naphthalimide-H),7.29(d,J=8.2Hz,1H,naphthalimide-H),3.50(d,J=2.3Hz,2H,CH 2 CCH),3.43(s,4H,piperidine-H),2.95–2.94(m,4H,piperidine-H),2.37(t,J=2.2Hz,1H,CH)ppm。
experimental example 16
Preparation of Compound I-14
A50 mL round bottom flask was charged with intermediate III (466 mg,1.4 mmol), chloroacetonitrile (113mg, 1.5 mmol), and potassium carbonate (0.82g, 5.6 mmol) in acetonitrile (15 mL) at 80 ℃ under reflux for about 10h, followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and carrying out post-treatment such as column chromatography separation and drying to obtain compound I-14 (315 mg), wherein the yield is as follows: 75.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,DMSO-d6)δ8.80(s,2H,triazole-H),8.59(t,J=7.3Hz,2H,naphthalimide-H),8.49(d,J=8.2Hz,1H,naphthalimide-H),7.92(s,1H,naphthalimide-H),7.44(d,J=8.2Hz,1H,naphthalimide-H),3.91(s,2H,NCH 2 CN),3.36(s,4H,piperidine-H),2.86(d,J=4.0Hz,4H,piperidine-H)ppm。
experimental example 17
Preparation of Compound I-15
A50 mL round bottom flask was charged with intermediate III (466 mg,1.4 mmol), p-chlorobenzyl chloride (242mg, 1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-15 (315 mg) with a yield: 75.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.65(d,J=6.6Hz,1H,naphthalimide-H),8.57(d,J=8.2Hz,1H,naphthalimide-H),8.53(d,J=7.8Hz,1H,naphthalimide-H),8.30(s,2H,triazole-H),7.77(s,1H,naphthalimide-H),7.33(d,4H,Ph-Cl-H),7.26(s,1H,naphthalimide-H),3.65(s,2H,NCH 2 Ph),3.39(s,4H,piperidine-H),2.80(s,4H,piperidine-H)ppm。
experimental example 18
Preparation of Compound I-16
A50 mL round-bottom flask was charged with intermediate III (466 mg,1.4 mmol), m-chlorobenzyl chloride (242mg, 1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-16 (315 mg) with a yield: 75.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.65(dd,J=7.3,0.9Hz,1H,naphthalimide-H),8.58(d,J=8.2Hz,1H,naphthalimide-H),8.54(dd,J=8.4,0.8Hz,1H,naphthalimide-H),8.30(s,2H,triazole-H),7.77(dd,J=8.3,7.5Hz,1H,naphthalimide-H),7.41(s,1H,Ph-Cl-H),7.28(d,J=1.8Hz,4H,naphthalimide-H,Ph-Cl-H),3.66(s,2H,NCH 2 Ph),3.40(s,4H,piperidine-H),2.81(s,4H,piperidine-H).
experimental example 19
Preparation of Compound I-17
A50 mL round-bottom flask was charged with intermediate III (466 mg,1.4 mmol), 2, 4-dichlorobenzyl chloride (293mg, 1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as a solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-17 (315 mg) with a yield: 75.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.66(dd,J=7.3,0.9Hz,1H,naphthalimide-H),8.58(d,J=8.2Hz,1H,naphthalimide-H),8.55(dd,J=8.4,0.9Hz,1H,naphthalimide-H),8.30(s,2H,triazole-H),7.78(dd,J=8.3,7.5Hz,1H,naphthalimide-H),7.48(d,J=8.1Hz,1H,Ph-Cl-H),7.41(d,J=2.0Hz,1H,Ph-Cl-H),7.28–7.26(m,2H,naphthalimide-H,Ph-Cl-H),3.76(s,2H,NCH 2 Ph),3.39(s,4H,piperidine-H),2.87(s,4H,piperidine-H)ppm。
experimental example 20
Preparation of Compound I-18
A50 mL round bottom flask was charged with intermediate III (466mg, 1.4mmol), p-fluorobenzyl bromide (284mg, 1.5mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-18 (315 mg) with a yield: 75.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.65(d,J=7.3Hz,1H,naphthalimide-H),8.57(d,J=8.2Hz,1H,naphthalimide-H),8.54(d,J=8.4Hz,1H,naphthalimide-H),8.30(s,2H,triazole-H),7.77(s,1H,naphthalimide-H),7.37(d,J=5.8Hz,2H,Ph-F-H),7.26(s,1H,naphthalimide-H),7.04(s,2H,Ph-Cl-H),3.65(s,2H,NCH 2 Ph),3.39(s,4H,piperidine-H),2.80(s,4H,piperidine-H).
experimental example 21
Preparation of Compound I-19
A50 mL round bottom flask was charged with intermediate III (466 mg, 1.4mmol), m-fluorobenzyl bromide (284mg, 1.5mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, passing through a column layerAfter separation, drying and the like, compound I-19 (315 mg) was obtained, yield: 75.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,DMSO-d6)δ8.80(s,2H,triazole-H),8.58–8.56(m,2H,naphthalimide-H),8.48(d,J=8.2Hz,1H,naphthalimide-H),7.90–7.87(m,1H,naphthalimide-H),7.41(d,J=3.7Hz,2H,naphthalimide-H,Ph-F-H),7.23(m,2H,Ph-F-H),7.12(m,1H,Ph-F-H),3.67(s,2H,NCH 2 Ph),2.74(s,4H),2.50(s,4H)ppm。
experimental example 22
Preparation of Compound I-20
A50 mL round-bottom flask was charged with intermediate III (466 mg,1.4 mmol), 2, 4-difluorobenzyl bromide (311mg, 1.5 mmol), potassium carbonate (0.82g, 5.6 mmol), acetonitrile (15 mL) as solvent, refluxed at 80 ℃ for about 10h, and followed by thin layer chromatography until the reaction was complete. Pouring the reaction solution into ice water, filtering, washing with ice water, and performing column chromatography separation, drying and other post-treatments to obtain a compound I-20 (315 mg) with a yield: 75.2 percent; a yellow solid; melting point:>250℃。 1 H NMR(600MHz,CDCl 3 )δ8.65(d,J=7.3Hz,1H,naphthalimide-H),8.57(d,J=8.2Hz,1H,naphthalimide-H),8.53(d,J=8.4Hz,1H,naphthalimide-H),8.30(s,2H,triazole-H),7.77(s,1H,naphthalimide-H),7.42(d,J=7.2Hz,1H,Ph-F-H),7.26(d,J=8.3Hz,1H,naphthalimide-H),6.90(dd,J=8.2,6.5Hz,1H,Ph-F-H),6.84(dd,J=8.8,7.6Hz,1H,Ph-F-H),3.72(s,2H,NCH 2 Ph),3.39(s,4H,piperidine-H),2.84(s,4H,piperidine-H)ppm。
example 23
In vitro antimicrobial activity of naphthalimide piperazine triazole compound
The nadir inhibitory concentrations (MIC) of the naphthoylimine piperazine triazole compounds prepared in examples 2 to 22 against gram-positive bacteria (methicillin-resistant Staphylococcus aureus, enterococcus faecalis, staphylococcus aureus ATCC25923, staphylococcus aureus ATCC 29213), gram-negative bacteria (Klebsiella pneumoniae, escherichia coli, pseudomonas aeruginosa ATCC27853, escherichia coli ATCC25922, acinetobacter baumannii) and fungi (Candida albicans, candida tropicalis, aspergillus fumigatus, candida albicans ATCC90023, and Candida parapsilosis ATCC 20019) were determined by 96-well microdilution method in accordance with the Clinical Laboratory Standards of the national Committee, CLSI, and the MIC results were determined by measuring the MIC concentrations of 1.28mg/mL of the naphthoylimine piperazine triazole compounds prepared in examples 2 to 22, diluting the test compounds with a small amount of dimethyl sulfoxide, adding water to a solution of a concentration of 128. Mu.g/mL, culturing at 35 ℃ for 24 to 72 hours, shaking the culture plates to a shaker sufficiently, and measuring the MIC results at 490nm of the wavelength of 1 to 3 nm of the Candida acinosa.
TABLE 1 in vitro gram-positive activity data (MIC, μ g/mL) for the naphthalimide piperazine triazole compounds prepared in examples 2-22
As can be seen from Table 1, the naphthalimide piperazine triazole compounds prepared in examples 2-22 of the invention have certain inhibitory effect on the tested gram-positive bacteria, and a part of compounds such as I-5 have moderate inhibitory activity on Staphylococcus aureus.
TABLE 2 in vitro gram negative bacteria resistance data (MIC, μ g/mL) for the naphthalimide piperazine triazole compounds prepared in examples 2-22
As can be seen from Table 2, the naphthalimide piperazine triazole compounds of examples 2-22 of the present invention showed certain inhibitory effect on the tested gram-negative bacteria. I-1 to I-4, I-6, I-7, I-12, I-13, I-15 to I-18 and I-20 show the inhibition activity on acinetobacter baumannii which is equivalent to that of the reference medicament norfloxacin.
TABLE 3 data on the antifungal Activity in vitro (MIC, μ g/mL) of the Naphthoimidopiperazine triazole Compounds prepared in examples 2-22
As can be seen from Table 3, the antifungal activity of the naphthalimide piperazine triazole compounds prepared in examples 2-22 of the present invention is generally superior to their antibacterial activity. MIC =4 μ g/mL for dodecyl substituted compound I-5 against candida parapsilosis ATCC22019, comparable to the reference drug fluconazole. The compound I-5 has good inhibition activity (MIC =4 mug/mL) on the aspergillus fumigatus, is 32 times that of the reference drug fluconazole, and is superior to the reference drug fluconazole; the 2, 4-dichlorophenyl substituted compound I-17 showed good activity against aspergillus fumigatus, with MIC =2 μ g/mL, 64 times that of the reference drug fluconazole; in particular, propargyl-substituted compound I-13, had 128-fold higher inhibitory activity against aspergillus fumigatus (MIC =1 μ g/mL) than the reference drug fluconazole.
Example 24
Pharmaceutical application of naphthalimide piperazine triazole compound
According to the antimicrobial activity detection result, the naphthalimide piperazine triazole compound has good antibacterial and antifungal activity, and can be prepared into antibacterial and antifungal medicines for clinical use. The medicines can be single-component preparations, for example, the medicines are prepared from naphthalimide piperazine triazole compounds with one structure and pharmaceutically acceptable auxiliary materials; or a compound preparation, for example, the compound is prepared by the naphthalimide piperazine triazole compound with one structure, the existing antibacterial and antifungal active ingredients (such as norfloxacin, sulfamethoxazole, fluconazole, phosphorus fluconazole, itraconazole and the like) and pharmaceutically acceptable auxiliary materials, or the compound is prepared by a plurality of naphthalimide piperazine triazole compounds with different structures and pharmaceutically acceptable auxiliary materials. The preparation types include, but are not limited to, tablets, capsules, powders, granules, dripping pills, injections, powder injections, solutions, suspensions, emulsions, suppositories, ointments, gels, films, aerosols, transdermal patches and other dosage forms, and various sustained-release and controlled-release preparations and nano preparations.
1. Preparation of Compound I-4 tablets
Prescription: the tablet is prepared from compound I-410g, lactose 187g, corn starch 50g, magnesium stearate 3g, and ethanol solution with volume percentage concentration of 70% in a proper amount, and is prepared into 1000 tablets.
The preparation method comprises the following steps: drying corn starch at 105 deg.C for 5 hr; mixing compound I-4 with lactose and corn starch, making soft mass with 70% ethanol solution, sieving to obtain wet granule, adding magnesium stearate, and tabletting; each tablet weighs 250mg, and the content of active ingredients is 10mg.
2. Preparation of Compound I-2 Capsule
Prescription: 2-25g of compound I, 12.5g of modified starch (120 meshes), 7.5g of microcrystalline cellulose (100 meshes), 2.5g of low-substituted hydroxypropyl cellulose (100 meshes), 2g of talcum powder (100 meshes), 1.25g of sweetener, 0.25g of orange essence, a proper amount of pigment and a proper amount of water, and the granules are prepared into 1000 granules.
The preparation method comprises the following steps: micronizing compound I-2 into superfine powder, mixing with modified starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, pulvis Talci, sweetener, orange essence and pigment, granulating with water, sieving with 12-14 mesh sieve, drying at 40-50 deg.C, sieving, grading, and making into capsule; each tablet weighs 50mg, and the content of active ingredient is 25mg.
3. Preparation of Compound I-5 granules
Prescription: 26g of compound I-5, 120g of dextrin and 280g of sucrose.
The preparation method comprises the following steps: mixing compound I-5, dextrin and sucrose uniformly, granulating by wet method, drying at 60 deg.C, and packaging.
4. Preparation of Compound I-17 injection
Prescription: compound I-17 (10 g), propylene glycol (500 mL), and water for injection (500 mL) were prepared in a total volume of 1000mL.
The preparation method comprises the following steps: weighing the compound I-17, adding propylene glycol and injection water, stirring for dissolving, adding 1g of activated carbon, fully stirring, standing for 15 minutes, filtering with a 5-micron titanium rod for decarbonization, sequentially fine-filtering with microporous filter membranes with the pore diameters of 0.45 micron and 0.22 micron, finally encapsulating in a 10mL ampoule, and sterilizing with 100 ℃ circulating steam for 45 minutes to obtain the compound I-17.
5. Preparation of compound I-13 powder injection
The preparation method comprises the following steps: and subpackaging the sterile powder of the compound I-13 under the aseptic condition to obtain the compound I-13.
6. Preparation of Compound I-13 eye drops
Prescription: 3.78g of compound I-13, 0.9g of sodium chloride, a proper amount of boric acid buffer solution and distilled water are added to 1000mL.
The preparation method comprises the following steps: weighing the compound I-13 and sodium chloride, adding into 500mL of distilled water, dissolving completely, adjusting pH to 6.5 with boric acid buffer solution, adding distilled water to 1000mL, stirring well, filtering with microporous membrane, bottling, sealing, and sterilizing with 100 deg.C flowing steam for 1 hr.
7. Preparation of Compound I-13 Liniment
Prescription: compound I-13 g, potassium soap 7.5g, camphor 5g, distilled water added to 100mL.
The preparation method comprises the following steps: dissolving camphor with 95 percent ethanol solution by volume percentage for later use; heating potassium soap to liquefy, weighing compound I-13, adding potassium soap solution and Camphora ethanol solution under stirring, gradually adding distilled water, emulsifying completely, and adding distilled water to full volume.
8. Preparation of suppository of compound I-13
Prescription: compound I-13 g, gelatin 14g, glycerin 70g, distilled water to 100mL, total 100.
The preparation method comprises the following steps: weighing gelatin and glycerol, adding distilled water to 100mL, heating in water bath at 60 deg.C to melt into paste, adding compound I-13, stirring, pouring into vaginal suppository mold when it is nearly solidified, and cooling for solidification.
9. Preparation of Compound I-13 ointment
Prescription: 0.5-2g of compound I-13, 6-8g of hexadecanol, 8-10g of white vaseline, 8-19g of liquid paraffin, 2-5g of monoglyceride, 2-5g of polyoxyethylene (40) stearate, 5-10g of glycerol, 0.1g of ethylparaben and distilled water added to 100g.
The preparation method comprises the following steps: heating cetyl alcohol, white vaseline, liquid paraffin, monoglyceride and polyoxyethylene (40) stearate to completely dissolve, mixing, and keeping the temperature at 80 deg.C to obtain oil phase; adding ethylparaben into glycerol and distilled water, heating to 85 deg.C for dissolving, adding oil phase under stirring, emulsifying, adding compound I-13, stirring, and cooling.
10. Preparation of compound I-20 and fluconazole compound powder injection
Prescription: compound I-20 50g, fluconazole 50g and sodium benzoate 1g, and 100 bottles are prepared.
The preparation method comprises the following steps: taking the compound I-20, the fluconazole and the sodium benzoate according to the prescription amount, uniformly mixing in a sterile state, and subpackaging 100 bottles to obtain the compound I-20.
11. Preparation of Compound I-20 Aerosol
Prescription: compound I-20.5g, span20 3g, talc (100 mesh) 4g, trichlorofluoromethane to appropriate amount.
The preparation method comprises the following steps: respectively placing the compound I-20, the Span20 and the talcum powder in a vacuum drying oven for drying for several hours, placing in a dryer for cooling to room temperature, crushing into micro powder by using an airflow crusher, uniformly mixing according to the prescription amount, filling into a closed container, and adding trichloromonofluoromethane to a specified amount to obtain the trichloromonofluoromethane.
Finally, the above embodiments are only intended to illustrate the technical solutions of the present invention and not to limit the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it will be understood by those skilled in the art that modifications or equivalent substitutions may be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions, and all of them should be covered by the claims of the present invention.
Claims (9)
2. the naphthalimide piperazine triazole compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable salt is a hydrochloride, nitrate or acetate salt.
3. The method for preparing the naphthalimide piperazine triazole compound according to claim 1, wherein the method comprises the following steps:
a. preparation of intermediate II: 4-bromo-1, 8-naphthalic anhydride is used as an initial raw material, ethanol is used as a solvent, zinc acetate is used as a catalyst, and the mixture reacts with 4-amino-1, 2, 4-triazole to obtain an intermediate II;
b. preparation of intermediate III: taking the intermediate II as a starting material, taking ethylene glycol monomethyl ether as a solvent, and reacting with anhydrous piperazine to obtain an intermediate III;
c. the preparation of the naphthalimide piperazine triazole compound shown in the formula I-1-20 is carried out by taking the intermediate III as a starting material, acetonitrile as a solvent and potassium carbonate as a catalyst, and reacting with different halides to obtain the naphthalimide piperazine triazole compound shown in the formula I-1-20.
4. The method according to claim 3,
in the step a, the reaction temperature is 80 ℃; the molar ratio of the 4-bromo-1, 8-naphthalic anhydride, 4-amino-1, 2, 4-triazole and zinc acetate is 1;
in the step b, the reaction temperature is 90 ℃; the molar ratio of the intermediate II to the anhydrous piperazine is 1;
in the step c, the reaction temperature is 80 ℃; the molar ratio of intermediate III, different halides and potassium carbonate is 1.07.
5. Use of the naphthalimide piperazine triazole compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2 for preparing antibacterial and/or antifungal medicaments.
6. The use of claim 5, wherein the bacteria is one or more of enterococcus faecalis, staphylococcus aureus, klebsiella pneumoniae, escherichia coli, pseudomonas aeruginosa or acinetobacter baumannii; the fungi is one or more of Candida albicans, candida tropicalis, aspergillus fumigatus or Candida parapsilosis ATCC 20019.
7. The use of claim 6, wherein the bacteria is one or more of methicillin-resistant staphylococcus aureus, staphylococcus aureus ATCC25923, staphylococcus aureus ATCC29213, escherichia coli ATCC25922, or pseudomonas aeruginosa ATCC 27853; the fungus is Candida albicans ATCC90023.
8. A formulation comprising the naphthalimide piperazine triazole compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof.
9. The formulation of claim 8, wherein the formulation is one of a tablet, a capsule, a granule, an injection, an eye drop, a liniment, a suppository, an ointment, or an aerosol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010305821.1A CN111518075B (en) | 2020-04-17 | 2020-04-17 | Naphthalimide piperazine triazole compound and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010305821.1A CN111518075B (en) | 2020-04-17 | 2020-04-17 | Naphthalimide piperazine triazole compound and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111518075A CN111518075A (en) | 2020-08-11 |
CN111518075B true CN111518075B (en) | 2023-03-28 |
Family
ID=71902126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010305821.1A Active CN111518075B (en) | 2020-04-17 | 2020-04-17 | Naphthalimide piperazine triazole compound and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111518075B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112521382A (en) * | 2020-12-14 | 2021-03-19 | 西南大学 | Aloe-emodin thiazolidinedione compound and preparation method and application thereof |
CN115636785B (en) * | 2022-09-23 | 2024-05-28 | 西南大学 | Quinolone cyanoacetate compound and pharmaceutically acceptable salt thereof, and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000032577A2 (en) * | 1998-11-25 | 2000-06-08 | Merck Patent Gmbh | Substituted benzo[de]isoquinoline-1,3-diones |
CN107629044A (en) * | 2017-10-25 | 2018-01-26 | 西南大学 | Naphthalimide aminothiazole class compound and its preparation method and application |
-
2020
- 2020-04-17 CN CN202010305821.1A patent/CN111518075B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000032577A2 (en) * | 1998-11-25 | 2000-06-08 | Merck Patent Gmbh | Substituted benzo[de]isoquinoline-1,3-diones |
CN1330638A (en) * | 1998-11-25 | 2002-01-09 | 默克专利股份公司 | Substituted benzo (de) isoquinoline-1,3-diones |
CN107629044A (en) * | 2017-10-25 | 2018-01-26 | 西南大学 | Naphthalimide aminothiazole class compound and its preparation method and application |
Non-Patent Citations (6)
Title |
---|
Meng Li等.Lysosomal tracking with a cationic naphthalimide using multiphoton fluorescence lifetime imaging microscopy.《Chem. Commun.》.2017,第11161-11164页. * |
Peng-Li Zhang等.An unanticipated discovery towards novel naphthalimide corbelled aminothiazoximes as potential anti-MRSA agents and allosteric modulators for PBP2a.《European Journal of Medicinal Chemistry》.2021,第1-20页. * |
张鹏丽.萘酰亚胺三唑新骨架结构化合物的合成及其抗烟曲霉菌作用.《中国科学》杂志社.2021,第51卷(第8期),第1094-1103页. * |
王华等.2-(2-羟基苯亚胺基)-6-哌嗪基-1H-苯并异喹啉-1,3-二酮的合成.《贵州工程应用技术学院学报》.2016,第34卷(第34期),第153-156页. * |
王艳等.三唑类药物研究新进展.《中国科学》杂志社.2011,第41卷(第9期),第1429-1456页. * |
袁玉坤.三唑类萘酰亚胺化合物的合成及生物活性研究.《中国优秀硕士学位论文全文数据库 工程科技I辑》.2010,第B014-24页. * |
Also Published As
Publication number | Publication date |
---|---|
CN111518075A (en) | 2020-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109942546B (en) | Quinolone pyrimidine compound and preparation method and application thereof | |
CN111518075B (en) | Naphthalimide piperazine triazole compound and preparation method and application thereof | |
CN109535176B (en) | Quinolone imidazole compound and preparation method and application thereof | |
CN107698567B (en) | Isatin azole alcohol compound and preparation method and medical application thereof | |
CN109734723B (en) | Ofloxacin thiazole analogue and preparation method and application thereof | |
CN110330489B (en) | Quinolone thiazole oxime compound and preparation method and application thereof | |
CN108440518B (en) | 3- (2-aminothiazole) -7-substituted piperazine quinolone compound and preparation method and application thereof | |
CN112661750B (en) | Ketene-bridged quinazolinone thiazole compound and preparation method and application thereof | |
CN111087388A (en) | Hydrazone group bridged naphthalimide imidazole compound and preparation method and application thereof | |
CN109575007B (en) | Aminothiazole isatin compound and preparation method and application thereof | |
CN111087392B (en) | Vinyl conjugated indolylaminothiazole compound and preparation method and application thereof | |
CN110396090B (en) | Imidazole alcohol tetrahydrocoptisane oxime conjugate and preparation method and application thereof | |
CN113292476B (en) | Sulfaindole derivative and preparation method and application thereof | |
CN110452224B (en) | Pyrimidineazolol compound and preparation method and application thereof | |
CN110028455B (en) | Schiff base nitroimidazole compound and preparation method and application thereof | |
CN112480105B (en) | Piperazine bridged naphthalimide aminothiazole oxime compound and preparation method and application thereof | |
CN112745317B (en) | Purine thiazole compound and preparation method and application thereof | |
CN108658971B (en) | tetrahydroberberine thiadione compound and preparation method and application thereof | |
CN112979652B (en) | Isopropanol bridged purine azole compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | |
CN111018853A (en) | Phenol berberine benzimidazole compound and preparation method and application thereof | |
CN114702486B (en) | Thiazolidinedione bridged metronidazole berberine compounds, and preparation method and application thereof | |
CN110041368B (en) | Organic phosphine clinafloxacin derivative and preparation method and application thereof | |
CN112194631B (en) | Schiff base bridged sulfaimidazole compound and preparation method and application thereof | |
CN112209881B (en) | Emodin oxazole compound and preparation method and application thereof | |
CN115490669B (en) | Indolal compound and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |